Heat shock proteins in multiple myeloma

Oncotarget

Volumn 5, Issue 5, 2014, Pages 1132-1148

  Zhang, Lei ^a   Fok, Jacqueline H L ^a   Davies, Faith E ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

ER stress; Haematology; Heat shock proteins; Multiple myeloma; Protein folding

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CHAPERONIN 60; DEXAMETHASONE; EARLY PREGNANCY FACTOR; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 110; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HEAT SHOCK TRANSCRIPTION FACTOR 1; KW 2478; LUMINESPIB; MAL 3 101; NVP HSP 990; PF 04929113; PU H 71; RETASPIMYCIN; SNX 5422; TANESPIMYCIN; UNCLASSIFIED DRUG; VER 155008; DNA BINDING PROTEIN; HEAT SHOCK TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELLULAR DISTRIBUTION; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; HUMAN; METASTASIS; MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; PROTEIN TARGETING; UNFOLDED PROTEIN RESPONSE; ANTAGONISTS AND INHIBITORS; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

CHAPERONIN 10; CHAPERONIN 60; DNA-BINDING PROTEINS; HEAT-SHOCK PROTEINS; HSP27 HEAT-SHOCK PROTEINS; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MULTIPLE MYELOMA; PROTEIN FOLDING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84898636988     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1584     Document Type: Article

References (200)

1. Craig EA. Chaperones: helpers along the pathways to protein folding. Science. 1993; 260(5116):1902-1903.
2. Hartl FU. Molecular chaperones in cellular protein folding. Nature. 1996; 381(6583):571-579.
3. Hartl FU and Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science. 2002; 295(5561):1852-1858.
4. Muralidharan S and Mandrekar P. Cellular stress response and innate immune signaling: integrating pathways in host defense and inflammation. J Leukoc Biol. 2013.
5. Udono H, Ichiyanagi T, Mizukami S and Imai T. Heat shock proteins in antigen trafficking--implications on antigen presentation to T cells. Int J Hyperthermia. 2009; 25(8):617-625.
6. Afzal E, Ebrahimi M, Najafi SM, Daryadel A and Baharvand H. Potential role of heat shock proteins in neural differentiation of murine embryonal carcinoma stem cells (P19). Cell Biol Int. 2011; 35(7):713-720.
7. Wiesgigl M and Clos J. Heat shock protein 90 homeostasis controls stage differentiation in Leishmania donovani. Mol Biol Cell. 2001; 12(11):3307-3316.
8. Christians ES, Zhou Q, Renard J and Benjamin IJ. Heat shock proteins in mammalian development. Semin Cell Dev Biol. 2003; 14(5):283-290.
9. Ritossa F. A new puffing pattern induced by temperature shock and DNP in drosophila. Experientia. 1962; 18(12):571-573.
10. Palumbo A and Anderson K. Multiple myeloma. N Engl J Med. 2011; 364(11):1046-1060.
11. Davenport EL, Moore HE, Dunlop AS, Sharp SY, Workman P, Morgan GJ and Davies FE. Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood. 2007; 110(7):2641-2649.
12. Richardson PG, Chanan-Khan AA, Alsina M, Albitar M, Berman D, Messina M, Mitsiades CS and Anderson KC. Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study. Br J Haematol. 2010; 150(4):438-445.
13. Richardson PG, Chanan-Khan AA, Lonial S, Krishnan AY, Carroll MP, Alsina M, Albitar M, Berman D, Messina M and Anderson KC. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. Br J Haematol. 2011; 153(6):729-740.
14. Stuhmer T, Zollinger A, Siegmund D, Chatterjee M, Grella E, Knop S, Kortum M, Unzicker C, Jensen MR, Quadt C, Chene P, Schoepfer J, Garcia-Echeverria C, Einsele H, Wajant H and Bargou RC. Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia. 2008; 22(8):1604-1612.
15. Nakashima T, Ishii T, Tagaya H, Seike T, Nakagawa H, Kanda Y, Akinaga S, Soga S and Shiotsu Y. New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells. Clin Cancer Res. 2010; 16(10):2792-2802.
16. Borkovich KA, Farrelly FW, Finkelstein DB, Taulien J and Lindquist S. hsp82 is an essential protein that is required in higher concentrations for growth of cells at higher temperatures. Mol Cell Biol. 1989; 9(9):3919-3930.
17. Zhao R, Davey M, Hsu YC, Kaplanek P, Tong A, Parsons AB, Krogan N, Cagney G, Mai D, Greenblatt J, Boone C, Emili A and Houry WA. Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone. Cell. 2005; 120(5):715- 727.
18. Aligue R, Akhavan-Niak H and Russell P. A role for Hsp90 in cell cycle control: Wee1 tyrosine kinase activity requires interaction with Hsp90. EMBO J. 1994; 13(24):6099-6106.
19. Chen CF, Chen Y, Dai K, Chen PL, Riley DJ and Lee WH. A new member of the hsp90 family of molecular chaperones interacts with the retinoblastoma protein during mitosis and after heat shock. Mol Cell Biol. 1996; 16(9):4691-4699.
20. Cutforth T and Rubin GM. Mutations in Hsp83 and cdc37 impair signaling by the sevenless receptor tyrosine kinase in Drosophila. Cell. 1994; 77(7):1027-1036.
21. Joab I, Radanyi C, Renoir M, Buchou T, Catelli MG, Binart N, Mester J and Baulieu EE. Common nonhormone binding component in non-transformed chick oviduct receptors of four steroid hormones. Nature. 1984; 308(5962):850-853.
22. Oppermann H, Levinson W and Bishop JM. A cellular protein that associates with the transforming protein of Rous sarcoma virus is also a heat-shock protein. Proc Natl Acad Sci U S A. 1981; 78(2):1067-1071.
23. Sepehrnia B, Paz IB, Dasgupta G and Momand J. Heat shock protein 84 forms a complex with mutant p53 protein predominantly within a cytoplasmic compartment of the cell. J Biol Chem. 1996; 271(25):15084-15090.
24. Stancato LF, Chow YH, Hutchison KA, Perdew GH, Jove R and Pratt WB. Raf exists in a native heterocomplex with hsp90 and p50 that can be reconstituted in a cell-free system. J Biol Chem. 1993; 268(29):21711-21716.
25. Pearl LH and Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem. 2006; 75:271-294.
26. Obermann WM, Sondermann H, Russo AA, Pavletich NP and Hartl FU. In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis. J Cell Biol. 1998; 143(4):901-910.
27. Panaretou B, Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW and Pearl LH. ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J. 1998; 17(16):4829-4836.
28. Csermely P, Kajtar J, Hollosi M, Jalsovszky G, Holly S, Kahn CR, Gergely P, Jr., Soti C, Mihaly K and Somogyi J. ATP induces a conformational change of the 90-kDa heat shock protein (hsp90). J Biol Chem. 1993; 268(3):1901- 1907.
29. Ali MM, Roe SM, Vaughan CK, Meyer P, Panaretou B, Piper PW, Prodromou C and Pearl LH. Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature. 2006; 440(7087):1013-1017.
30. Hessling M, Richter K and Buchner J. Dissection of the ATP-induced conformational cycle of the molecular chaperone Hsp90. Nat Struct Mol Biol. 2009; 16(3):287- 293.
31. Sato S, Fujita N and Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci U S A. 2000; 97(20):10832-10837.
32. Chen S, Sullivan WP, Toft DO and Smith DF. Differential interactions of p23 and the TPR-containing proteins Hop, Cyp40, FKBP52 and FKBP51 with Hsp90 mutants. Cell Stress Chaperones. 1998; 3(2):118-129.
33. Young JC, Obermann WM and Hartl FU. Specific binding of tetratricopeptide repeat proteins to the C-terminal 12- kDa domain of hsp90. J Biol Chem. 1998; 273(29):18007- 18010.
34. Marcu MG, Chadli A, Bouhouche I, Catelli M and Neckers LM. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J Biol Chem. 2000; 275(47):37181-37186.
35. Soti C, Racz A and Csermely P. A Nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket. J Biol Chem. 2002; 277(9):7066-7075.
36. Pratt WB, Galigniana MD, Harrell JM and DeFranco DB. Role of hsp90 and the hsp90-binding immunophilins in signalling protein movement. Cell Signal. 2004; 16(8):857- 872.
37. Sharp S and Workman P. Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res. 2006; 95:323- 348.
38. Whitesell L and Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005; 5(10):761-772.
39. Dittmar KD and Pratt WB. Folding of the glucocorticoid receptor by the reconstituted Hsp90-based chaperone machinery. The initial hsp90.p60.hsp70-dependent step is sufficient for creating the steroid binding conformation. J Biol Chem. 1997; 272(20):13047-13054.
40. Morishima Y, Murphy PJ, Li DP, Sanchez ER and Pratt WB. Stepwise assembly of a glucocorticoid receptor. hsp90 heterocomplex resolves two sequential ATPdependent events involving first hsp70 and then hsp90 in opening of the steroid binding pocket. J Biol Chem. 2000; 275(24):18054-18060.
41. Sullivan W, Stensgard B, Caucutt G, Bartha B, McMahon N, Alnemri ES, Litwack G and Toft D. Nucleotides and two functional states of hsp90. J Biol Chem. 1997; 272(12):8007-8012.
42. Altieri DC, Stein GS, Lian JB and Languino LR. TRAP- 1, the mitochondrial Hsp90. Biochim Biophys Acta. 2011; 1823(3):767-773.
43. Sciacovelli M, Guzzo G, Morello V, Frezza C, Zheng L, Nannini N, Calabrese F, Laudiero G, Esposito F, Landriscina M, Defilippi P, Bernardi P and Rasola A. The mitochondrial chaperone TRAP1 promotes neoplastic growth by inhibiting succinate dehydrogenase. Cell Metab. 2013; 17(6):988-999.
44. Melnick J, Dul JL and Argon Y. Sequential interaction of the chaperones BiP and GRP94 with immunoglobulin chains in the endoplasmic reticulum. Nature. 1994; 370(6488):373-375.
45. Christianson JC, Shaler TA, Tyler RE and Kopito RR. OS-9 and GRP94 deliver mutant alpha1-antitrypsin to the Hrd1- SEL1L ubiquitin ligase complex for ERAD. Nat Cell Biol. 2008; 10(3):272-282.
46. Eletto D, Dersh D and Argon Y. GRP94 in ER quality control and stress responses. Semin Cell Dev Biol. 2010; 21(5):479-485.
47. Mayer MP, Schroder H, Rudiger S, Paal K, Laufen T and Bukau B. Multistep mechanism of substrate binding determines chaperone activity of Hsp70. Nat Struct Biol. 2000; 7(7):586-593.
48. Liberek K, Marszalek J, Ang D, Georgopoulos C and Zylicz M. Escherichia coli DnaJ and GrpE heat shock proteins jointly stimulate ATPase activity of DnaK. Proc Natl Acad Sci U S A. 1991; 88(7):2874-2878.
49. Beckmann RP, Mizzen LE and Welch WJ. Interaction of Hsp 70 with newly synthesized proteins: implications for protein folding and assembly. Science. 1990; 248(4957):850-854.
50. Teter SA, Houry WA, Ang D, Tradler T, Rockabrand D, Fischer G, Blum P, Georgopoulos C and Hartl FU. Polypeptide flux through bacterial Hsp70: DnaK cooperates with trigger factor in chaperoning nascent chains. Cell. 1999; 97(6):755-765.
51. Thulasiraman V, Yang CF and Frydman J. In vivo newly translated polypeptides are sequestered in a protected folding environment. EMBO J. 1999; 18(1):85-95.
52. Ben-Zvi AP and Goloubinoff P. Review: mechanisms of disaggregation and refolding of stable protein aggregates by molecular chaperones. J Struct Biol. 2001; 135(2):84-93.
53. Mayer MP and Bukau B. Hsp70 chaperones: cellular functions and molecular mechanism. Cell Mol Life Sci. 2005; 62(6):670-684.
54. Mayer MP, Rudiger S and Bukau B. Molecular basis for interactions of the DnaK chaperone with substrates. Biol Chem. 2000; 381(9-10):877-885.
55. Pierpaoli EV, Sandmeier E, Baici A, Schonfeld HJ, Gisler S and Christen P. The power stroke of the DnaK/DnaJ/GrpE molecular chaperone system. J Mol Biol. 1997; 269(5):757- 768.
56. Slepenkov SV and Witt SN. The unfolding story of the Escherichia coli Hsp70 DnaK: is DnaK a holdase or an unfoldase? Mol Microbiol. 2002; 45(5):1197-1206.
57. De Los Rios P, Ben-Zvi A, Slutsky O, Azem A and Goloubinoff P. Hsp70 chaperones accelerate protein translocation and the unfolding of stable protein aggregates by entropic pulling. Proc Natl Acad Sci U S A. 2006; 103(16):6166-6171.
58. Qian SB, McDonough H, Boellmann F, Cyr DM and Patterson C. CHIP-mediated stress recovery by sequential ubiquitination of substrates and Hsp70. Nature. 2006; 440(7083):551-555.
59. Majeski AE and Dice JF. Mechanisms of chaperonemediated autophagy. Int J Biochem Cell Biol. 2004; 36(12):2435-2444.
60. Pratt WB. The role of the hsp90-based chaperone system in signal transduction by nuclear receptors and receptors signaling via MAP kinase. Annu Rev Pharmacol Toxicol. 1997; 37:297-326.
61. Hendershot L, Wei J, Gaut J, Melnick J, Aviel S and Argon Y. Inhibition of immunoglobulin folding and secretion by dominant negative BiP ATPase mutants. Proc Natl Acad Sci U S A. 1996; 93(11):5269-5274.
62. Ni M and Lee AS. ER chaperones in mammalian development and human diseases. FEBS Lett. 2007; 581(19):3641-3651.
63. Shen Y, Meunier L and Hendershot LM. Identification and characterization of a novel endoplasmic reticulum (ER) DnaJ homologue, which stimulates ATPase activity of BiP in vitro and is induced by ER stress. J Biol Chem. 2002; 277(18):15947-15956.
64. Delpino A and Castelli M. The 78 kDa glucose-regulated protein (GRP78/BIP) is expressed on the cell membrane, is released into cell culture medium and is also present in human peripheral circulation. Biosci Rep. 2002; 22(3- 4):407-420.
65. Gray PC and Vale W. Cripto/GRP78 modulation of the TGF-beta pathway in development and oncogenesis. FEBS Lett. 2012; 586(14):1836-1845.
66. Misra UK, Payne S and Pizzo SV. The monomeric receptor binding domain of tetrameric alpha2-macroglobulin binds to cell surface GRP78 triggering equivalent activation of signaling cascades. Biochemistry. 2013; 52(23):4014-4025.
67. Neupert W and Brunner M. The protein import motor of mitochondria. Nat Rev Mol Cell Biol. 2002; 3(8):555-565.
68. Brodsky JL, and Schekman, R. (1994). The Biology of Heat Shock Proteins and Molecular Chaperones Cold Spring Harbor Laboratory Press, Plainview, NY ).
69. Corsi AK and Schekman R. Mechanism of polypeptide translocation into the endoplasmic reticulum. J Biol Chem. 1996; 271(48):30299-30302.
70. Park SH, Bolender N, Eisele F, Kostova Z, Takeuchi J, Coffino P and Wolf DH. The cytoplasmic Hsp70 chaperone machinery subjects misfolded and endoplasmic reticulum import-incompetent proteins to degradation via the ubiquitin-proteasome system. Mol Biol Cell. 2007; 18(1):153-165.
71. Agarraberes FA, Terlecky SR and Dice JF. An intralysosomal hsp70 is required for a selective pathway of lysosomal protein degradation. J Cell Biol. 1997; 137(4):825-834.
72. Chiang HL, Terlecky SR, Plant CP and Dice JF. A role for a 70-kilodalton heat shock protein in lysosomal degradation of intracellular proteins. Science. 1989; 246(4928):382-385.
73. Evans CG, Chang L and Gestwicki JE. Heat shock protein 70 (hsp70) as an emerging drug target. J Med Chem. 2010; 53(12):4585-4602.
74. Sabirzhanov B, Stoica BA, Hanscom M, Piao CS and Faden AI. Over-expression of HSP70 attenuates caspasedependent and caspase-independent pathways and inhibits neuronal apoptosis. J Neurochem. 2012; 123(4):542-554.
75. Benesch JL, Ayoub M, Robinson CV and Aquilina JA. Small heat shock protein activity is regulated by variable oligomeric substructure. J Biol Chem. 2008; 283(42):28513-28517.
76. Garrido C, Paul C, Seigneuric R and Kampinga HH. The small heat shock proteins family: the long forgotten chaperones. Int J Biochem Cell Biol. 2012; 44(10):1588- 1592.
77. Bruey JM, Ducasse C, Bonniaud P, Ravagnan L, Susin SA, Diaz-Latoud C, Gurbuxani S, Arrigo AP, Kroemer G, Solary E and Garrido C. Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat Cell Biol. 2000; 2(9):645-652.
78. Charette SJ, Lavoie JN, Lambert H and Landry J. Inhibition of Daxx-mediated apoptosis by heat shock protein 27. Mol Cell Biol. 2000; 20(20):7602-7612.
79. Parcellier A, Schmitt E, Gurbuxani S, Seigneurin-Berny D, Pance A, Chantome A, Plenchette S, Khochbin S, Solary E and Garrido C. HSP27 is a ubiquitin-binding protein involved in I-kappaBalpha proteasomal degradation. Mol Cell Biol. 2003; 23(16):5790-5802.
80. Parcellier A, Brunet M, Schmitt E, Col E, Didelot C, Hammann A, Nakayama K, Nakayama KI, Khochbin S, Solary E and Garrido C. HSP27 favors ubiquitination and proteasomal degradation of p27Kip1 and helps S-phase reentry in stressed cells. FASEB J. 2006; 20(8):1179-1181.
81. McMullin TW and Hallberg RL. A highly evolutionarily conserved mitochondrial protein is structurally related to the protein encoded by the Escherichia coli groEL gene. Mol Cell Biol. 1988; 8(1):371-380.
82. Ostermann J, Horwich AL, Neupert W and Hartl FU. Protein folding in mitochondria requires complex formation with hsp60 and ATP hydrolysis. Nature. 1989; 341(6238):125-130.
83. Donald LJ, Stokell DJ, Holliday NJ, Ens W, Standing KG and Duckworth HW. Multiple equilibria of the Escherichia coli chaperonin GroES revealed by mass spectrometry. Protein Sci. 2005; 14(5):1375-1379.
84. Xu Z, Horwich AL and Sigler PB. The crystal structure of the asymmetric GroEL-GroES-(ADP)7 chaperonin complex. Nature. 1997; 388(6644):741-750.
85. Rye HS, Roseman AM, Chen S, Furtak K, Fenton WA, Saibil HR and Horwich AL. GroEL-GroES cycling: ATP and nonnative polypeptide direct alternation of foldingactive rings. Cell. 1999; 97(3):325-338.
86. Czarnecka AM, Campanella C, Zummo G and Cappello F. Mitochondrial chaperones in cancer: from molecular biology to clinical diagnostics. Cancer Biol Ther. 2006; 5(7):714-720.
87. Martin J. Molecular chaperones and mitochondrial protein folding. J Bioenerg Biomembr. 1997; 29(1):35-43.
88. Deocaris CC, Kaul SC and Wadhwa R. On the brotherhood of the mitochondrial chaperones mortalin and heat shock protein 60. Cell Stress Chaperones. 2006; 11(2):116-128.
89. Ghosh JC, Dohi T, Kang BH and Altieri DC. Hsp60 regulation of tumor cell apoptosis. J Biol Chem. 2008; 283(8):5188-5194.
90. Wadhwa R, Takano S, Kaur K, Aida S, Yaguchi T, Kaul Z, Hirano T, Taira K and Kaul SC. Identification and characterization of molecular interactions between mortalin/ mtHsp70 and HSP60. Biochem J. 2005; 391(Pt 2):185-190.
91. Chandra D, Choy G and Tang DG. Cytosolic accumulation of HSP60 during apoptosis with or without apparent mitochondrial release: evidence that its pro-apoptotic or pro-survival functions involve differential interactions with caspase-3. J Biol Chem. 2007; 282(43):31289-31301.
92. Feng H, Zeng Y, Graner MW and Katsanis E. Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells. Blood. 2002; 100(12):4108-4115.
93. Osterloh A, Meier-Stiegen F, Veit A, Fleischer B, von Bonin A and Breloer M. Lipopolysaccharide-free heat shock protein 60 activates T cells. J Biol Chem. 2004; 279(46):47906-47911.
94. Anraku I, Rajasuriar R, Dobbin C, Brown R, Lewin SR and Suhrbier A. Circulating heat shock protein 60 levels are elevated in HIV patients and are reduced by anti-retroviral therapy. PLoS One. 2012; 7(9):e45291.
95. Lewthwaite J, Owen N, Coates A, Henderson B and Steptoe A. Circulating human heat shock protein 60 in the plasma of British civil servants: relationship to physiological and psychosocial stress. Circulation. 2002; 106(2):196-201.
96. Dragovic Z, Broadley SA, Shomura Y, Bracher A and Hartl FU. Molecular chaperones of the Hsp110 family act as nucleotide exchange factors of Hsp70s. EMBO J. 2006; 25(11):2519-2528.
97. Ishihara K, Yamagishi N, Saito Y, Adachi H, Kobayashi Y, Sobue G, Ohtsuka K and Hatayama T. Hsp105alpha suppresses the aggregation of truncated androgen receptor with expanded CAG repeats and cell toxicity. J Biol Chem. 2003; 278(27):25143-25150.
98. Oh HJ, Chen X and Subjeck JR. Hsp110 protects heatdenatured proteins and confers cellular thermoresistance. J Biol Chem. 1997; 272(50):31636-31640.
99. Xu X, Sarbeng EB, Vorvis C, Kumar DP, Zhou L and Liu Q. Unique peptide substrate binding properties of 110- kDa heat-shock protein (Hsp110) determine its distinct chaperone activity. J Biol Chem. 2011; 287(8):5661-5672.
100. Baler R, Dahl G and Voellmy R. Activation of human heat shock genes is accompanied by oligomerization, modification, and rapid translocation of heat shock transcription factor HSF1. Mol Cell Biol. 1993; 13(4):2486- 2496.
101. Sarge KD, Murphy SP and Morimoto RI. Activation of heat shock gene transcription by heat shock factor 1 involves oligomerization, acquisition of DNA-binding activity, and nuclear localization and can occur in the absence of stress. Mol Cell Biol. 1993; 13(3):1392-1407.
102. Hahn JS, Hu Z, Thiele DJ and Iyer VR. Genome-wide analysis of the biology of stress responses through heat shock transcription factor. Mol Cell Biol. 2004; 24(12):5249-5256.
103. Page TJ, Sikder D, Yang L, Pluta L, Wolfinger RD, Kodadek T and Thomas RS. Genome-wide analysis of human HSF1 signaling reveals a transcriptional program linked to cellular adaptation and survival. Mol Biosyst. 2006; 2(12):627-639.
104. Trinklein ND, Murray JI, Hartman SJ, Botstein D and Myers RM. The role of heat shock transcription factor 1 in the genome-wide regulation of the mammalian heat shock response. Mol Biol Cell. 2004; 15(3):1254-1261.
105. Biaoxue R, Xiling J, Shuanying Y, Wei Z, Xiguang C, Jinsui W and Min Z. Upregulation of Hsp90-beta and annexin A1 correlates with poor survival and lymphatic metastasis in lung cancer patients. J Exp Clin Cancer Res. 2012; 31:70.
106. Chant ID, Rose PE and Morris AG. Analysis of heat-shock protein expression in myeloid leukaemia cells by flow cytometry. Br J Haematol. 1995; 90(1):163-168.
107. McCarthy MM, Pick E, Kluger Y, Gould-Rothberg B, Lazova R, Camp RL, Rimm DL and Kluger HM. HSP90 as a marker of progression in melanoma. Ann Oncol. 2008; 19(3):590-594.
108. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE, Morgan G, Akiyama M, Shringarpure R, Munshi NC, Richardson PG, Hideshima T, Chauhan D, Gu X, Bailey C, Joseph M, et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood. 2006; 107(3):1092- 1100.
109. Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL and Kluger HM. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res. 2007; 67(7):2932-2937.
110. Hanahan D and Weinberg RA. The hallmarks of cancer. Cell. 2000; 100(1):57-70.
111. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-674.
112. Wang J, Cui S, Zhang X, Wu Y and Tang H. High expression of heat shock protein 90 is associated with tumor aggressiveness and poor prognosis in patients with advanced gastric cancer. PLoS One. 2013; 8(4):e62876.
113. Zackova M, Mouckova D, Lopotova T, Ondrackova Z, Klamova H and Moravcova J. Hsp90 - a potential prognostic marker in CML. Blood Cells Mol Dis. 2012; 50(3):184-189.
114. Ciocca DR and Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones. 2005; 10(2):86-103.
115. Pocaly M, Lagarde V, Etienne G, Ribeil JA, Claverol S, Bonneu M, Moreau-Gaudry F, Guyonnet-Duperat V, Hermine O, Melo JV, Dupouy M, Turcq B, Mahon FX and Pasquet JM. Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia. Leukemia. 2007; 21(1):93-101.
116. Yang X, Wang J, Zhou Y, Wang Y, Wang S and Zhang W. Hsp70 promotes chemoresistance by blocking Bax mitochondrial translocation in ovarian cancer cells. Cancer Lett. 2012; 321(2):137-143.
117. Murphy ME. The HSP70 family and cancer. Carcinogenesis. 2013; 34(6):1181-1188.
118. Yang J, Hong Y, Wang W, Wu W, Chi Y, Zong H, Kong X, Wei Y, Yun X, Cheng C, Chen K and Gu J. HSP70 protects BCL2L12 and BCL2L12A from N-terminal ubiquitinationmediated proteasomal degradation. FEBS Lett. 2009; 583(9):1409-1414.
119. Stankiewicz AR, Lachapelle G, Foo CP, Radicioni SM and Mosser DD. Hsp70 inhibits heat-induced apoptosis upstream of mitochondria by preventing Bax translocation. J Biol Chem. 2005; 280(46):38729-38739.
120. Saleh A, Srinivasula SM, Balkir L, Robbins PD and Alnemri ES. Negative regulation of the Apaf-1 apoptosome by Hsp70. Nat Cell Biol. 2000; 2(8):476-483.
121. Beere HM, Wolf BB, Cain K, Mosser DD, Mahboubi A, Kuwana T, Tailor P, Morimoto RI, Cohen GM and Green DR. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol. 2000; 2(8):469-475.
122. Ravagnan L, Gurbuxani S, Susin SA, Maisse C, Daugas E, Zamzami N, Mak T, Jaattela M, Penninger JM, Garrido C and Kroemer G. Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat Cell Biol. 2001; 3(9):839- 843.
123. Ruchalski K, Mao H, Li Z, Wang Z, Gillers S, Wang Y, Mosser DD, Gabai V, Schwartz JH and Borkan SC. Distinct hsp70 domains mediate apoptosis-inducing factor release and nuclear accumulation. J Biol Chem. 2006; 281(12):7873-7880.
124. Mosser DD, Caron AW, Bourget L, Meriin AB, Sherman MY, Morimoto RI and Massie B. The chaperone function of hsp70 is required for protection against stress-induced apoptosis. Mol Cell Biol. 2000; 20(19):7146-7159.
125. Volloch V, Gabai VL, Rits S and Sherman MY. ATPase activity of the heat shock protein hsp72 is dispensable for its effects on dephosphorylation of stress kinase JNK and on heat-induced apoptosis. FEBS Lett. 1999; 461(1-2):73-76.
126. Yaglom JA, Gabai VL, Meriin AB, Mosser DD and Sherman MY. The function of HSP72 in suppression of c-Jun N-terminal kinase activation can be dissociated from its role in prevention of protein damage. J Biol Chem. 1999; 274(29):20223-20228.
127. Gabai VL, Yaglom JA, Waldman T and Sherman MY. Heat shock protein Hsp72 controls oncogene-induced senescence pathways in cancer cells. Mol Cell Biol. 2009; 29(2):559- 569.
128. Meng L, Gabai VL and Sherman MY. Heat-shock transcription factor HSF1 has a critical role in human epidermal growth factor receptor-2-induced cellular transformation and tumorigenesis. Oncogene. 2010; 29(37):5204-5213.
129. Meng L, Hunt C, Yaglom JA, Gabai VL and Sherman MY. Heat shock protein Hsp72 plays an essential role in Her2-induced mammary tumorigenesis. Oncogene. 2011; 30(25):2836-2845.
130. Nylandsted J, Gyrd-Hansen M, Danielewicz A, Fehrenbacher N, Lademann U, Hoyer-Hansen M, Weber E, Multhoff G, Rohde M and Jaattela M. Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization. J Exp Med. 2004; 200(4):425-435.
131. Ryhanen T, Hyttinen JM, Kopitz J, Rilla K, Kuusisto E, Mannermaa E, Viiri J, Holmberg CI, Immonen I, Meri S, Parkkinen J, Eskelinen EL, Uusitalo H, Salminen A and Kaarniranta K. Crosstalk between Hsp70 molecular chaperone, lysosomes and proteasomes in autophagymediated proteolysis in human retinal pigment epithelial cells. J Cell Mol Med. 2009; 13(9B):3616-3631.
132. Cuervo AM and Dice JF. A receptor for the selective uptake and degradation of proteins by lysosomes. Science. 1996; 273(5274):501-503.
133. Yu Z, Zhi J, Peng X, Zhong X and Xu A. Clinical significance of HSP27 expression in colorectal cancer. Mol Med Rep. 2011; 3(6):953-958.
134. Conroy SE, Sasieni PD, Amin V, Wang DY, Smith P, Fentiman IS and Latchman DS. Antibodies to heat-shock protein 27 are associated with improved survival in patients with breast cancer. Br J Cancer. 1998; 77(11):1875-1879.
135. Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, Fordham M, Neoptolemos JP, Ke Y and Foster CS. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res. 2000; 60(24):7099-7105.
136. Arts HJ, Hollema H, Lemstra W, Willemse PH, De Vries EG, Kampinga HH and Van der Zee AG. Heat-shockprotein- 27 (hsp27) expression in ovarian carcinoma: relation in response to chemotherapy and prognosis. Int J Cancer. 1999; 84(3):234-238.
137. Gibert B, Eckel B, Gonin V, Goldschneider D, Fombonne J, Deux B, Mehlen P, Arrigo AP, Clezardin P and Diaz- Latoud C. Targeting heat shock protein 27 (HspB1) interferes with bone metastasis and tumour formation in vivo. Br J Cancer. 2012; 107(1):63-70.
138. Wei L, Liu TT, Wang HH, Hong HM, Yu AL, Feng HP and Chang WW. Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelialmesenchymal transition and nuclear factor-kappaB. Breast Cancer Res. 2011; 13(5):R101.
139. Mizutani H, Okano T, Minegishi Y, Matsuda K, Sudoh J, Kitamura K, Noro R, Soeno C, Yoshimura A, Seike M and Gemma A. HSP27 modulates epithelial to mesenchymal transition of lung cancer cells in a Smad-independent manner. Oncol Lett. 2010; 1(6):1011-1016.
140. Shiota M, Bishop JL, Nip KM, Zardan A, Takeuchi A, Cordonnier T, Beraldi E, Bazov J, Fazli L, Chi K, Gleave M and Zoubeidi A. Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. Cancer Res. 2013; 73(10):3109-3119.
141. Thuringer D, Jego G, Wettstein G, Terrier O, Cronier L, Yousfi N, Hebrard S, Bouchot A, Hazoume A, Joly AL, Gleave M, Rosa-Calatrava M, Solary E and Garrido C. Extracellular HSP27 mediates angiogenesis through Tolllike receptor 3. FASEB J. 2013; 27(10):4169-4183.
142. Straume O, Shimamura T, Lampa MJ, Carretero J, Oyan AM, Jia D, Borgman CL, Soucheray M, Downing SR, Short SM, Kang SY, Wang S, Chen L, Collett K, Bachmann I, Wong KK, et al. Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. Proc Natl Acad Sci U S A. 2012; 109(22):8699-8704.
143. Cappello F, Conway de Macario E, Marasa L, Zummo G and Macario AJ. Hsp60 expression, new locations, functions and perspectives for cancer diagnosis and therapy. Cancer Biol Ther. 2008; 7(6):801-809.
144. Kirchhoff SR, Gupta S and Knowlton AA. Cytosolic heat shock protein 60, apoptosis, and myocardial injury. Circulation. 2002; 105(24):2899-2904.
145. Xanthoudakis S, Roy S, Rasper D, Hennessey T, Aubin Y, Cassady R, Tawa P, Ruel R, Rosen A and Nicholson DW. Hsp60 accelerates the maturation of pro-caspase-3 by upstream activator proteases during apoptosis. EMBO J. 1999; 18(8):2049-2056.
146. Tsai YP, Yang MH, Huang CH, Chang SY, Chen PM, Liu CJ, Teng SC and Wu KJ. Interaction between HSP60 and beta-catenin promotes metastasis. Carcinogenesis. 2009; 30(6):1049-1057.
147. Barazi HO, Zhou L, Templeton NS, Krutzsch HC and Roberts DD. Identification of heat shock protein 60 as a molecular mediator of alpha 3 beta 1 integrin activation. Cancer Res. 2002; 62(5):1541-1548.
148. Cappello F, David S, Rappa F, Bucchieri F, Marasa L, Bartolotta TE, Farina F and Zummo G. The expression of HSP60 and HSP10 in large bowel carcinomas with lymph node metastase. BMC Cancer. 2005; 5:139.
149. Shan YX, Liu TJ, Su HF, Samsamshariat A, Mestril R and Wang PH. Hsp10 and Hsp60 modulate Bcl-2 family and mitochondria apoptosis signaling induced by doxorubicin in cardiac muscle cells. J Mol Cell Cardiol. 2003; 35(9):1135- 1143.
150. Lin KM, Hollander JM, Kao VY, Lin B, Macpherson L and Dillmann WH. Myocyte protection by 10 kD heat shock protein (Hsp10) involves the mobile loop and attenuation of the Ras GTP-ase pathway. FASEB J. 2004; 18(9):1004- 1006.
151. Akyol S, Gercel-Taylor C, Reynolds LC and Taylor DD. HSP-10 in ovarian cancer: expression and suppression of T-cell signaling. Gynecol Oncol. 2006; 101(3):481-486.
152. Park HS, Park CH, Choi BR, Lim MS, Heo SH, Kim CH, Kang SG, Whang KU and Cho MK. Expression of heat shock protein 105 and 70 in malignant melanoma and benign melanocytic nevi. J Cutan Pathol. 2009; 36(5):511- 516.
153. Slaby O, Sobkova K, Svoboda M, Garajova I, Fabian P, Hrstka R, Nenutil R, Sachlova M, Kocakova I, Michalek J, Smerdova T, Knoflickova D and Vyzula R. Significant overexpression of Hsp110 gene during colorectal cancer progression. Oncol Rep. 2009; 21(5):1235-1241.
154. Ribeiro-Oliveira A, Jr., Franchi G, Kola B, Dalino P, Pinheiro SV, Salahuddin N, Musat M, Goth MI, Czirjak S, Hanzely Z, da Silva DA, Paulino E, Jr., Grossman AB and Korbonits M. Protein western array analysis in human pituitary tumours: insights and limitations. Endocr Relat Cancer. 2008; 15(4):1099-1114.
155. Muchemwa FC, Nakatsura T, Fukushima S, Nishimura Y, Kageshita T and Ihn H. Differential expression of heat shock protein 105 in melanoma and melanocytic naevi. Melanoma Res. 2008; 18(3):166-171.
156. Nakajima M, Kato H, Miyazaki T, Fukuchi M, Masuda N, Fukai Y, Sohda M, Inose T, Sakai M, Sano A, Tanaka N, Ahmad F and Kuwano H. Prognostic significance of heat shock protein 110 expression and T lymphocyte infiltration in esophageal cancer. Hepatogastroenterology. 2011; 58(110-111):1555-1560.
157. Dorard C, de Thonel A, Collura A, Marisa L, Svrcek M, Lagrange A, Jego G, Wanherdrick K, Joly AL, Buhard O, Gobbo J, Penard-Lacronique V, Zouali H, Tubacher E, Kirzin S, Selves J, et al. Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis. Nat Med. 2011; 17(10):1283- 1289.
158. Workman P and Davies FE. A stressful life (or death): combinatorial proteotoxic approaches to cancer-selective therapeutic vulnerability. Oncotarget. 2011; 2(4):277-280.
159. Meusser B, Hirsch C, Jarosch E and Sommer T. ERAD: the long road to destruction. Nat Cell Biol. 2005; 7(8):766-772.
160. Aronson LI, Davenport EL, Mirabella F, Morgan GJ and Davies FE. Understanding the interplay between the proteasome pathway and autophagy in response to dual PI3K/mTOR inhibition in myeloma cells is essential for their effective clinical application. Leukemia. 2013.
161. Aronson LI and Davies FE. DangER: protein ovERload. Targeting protein degradation to treat myeloma. Haematologica. 2012; 97(8):1119-1130.
162. Hoang B, Benavides A, Shi Y, Frost P and Lichtenstein A. Effect of autophagy on multiple myeloma cell viability. Mol Cancer Ther. 2009; 8(7):1974-1984.
163. Levine B and Klionsky DJ. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell. 2004; 6(4):463-477.
164. Mathew R, Karantza-Wadsworth V and White E. Role of autophagy in cancer. Nat Rev Cancer. 2007; 7(12):961-967.
165. Johnston JA, Ward CL and Kopito RR. Aggresomes: a cellular response to misfolded proteins. J Cell Biol. 1998; 143(7):1883-1898.
166. Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol. 2000; 10(12):524-530.
167. Garcia-Mata R, Gao YS and Sztul E. Hassles with taking out the garbage: aggravating aggresomes. Traffic. 2002; 3(6):388-396.
168. Taylor JP, Tanaka F, Robitschek J, Sandoval CM, Taye A, Markovic-Plese S and Fischbeck KH. Aggresomes protect cells by enhancing the degradation of toxic polyglutaminecontaining protein. Hum Mol Genet. 2003; 12(7):749-757.
169. Khong T and Spencer A. Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma. Mol Cancer Ther. 2011; 10(10):1909-1917.
170. Marcu MG, Doyle M, Bertolotti A, Ron D, Hendershot L and Neckers L. Heat shock protein 90 modulates the unfolded protein response by stabilizing IRE1alpha. Mol Cell Biol. 2002; 22(24):8506-8513.
171. Walsby E, Pearce L, Burnett AK, Fegan C and Pepper C. The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-kappaB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells. Oncotarget. 2012; 3(5):525-534.
172. Stuhmer T, Chatterjee M, Grella E, Seggewiss R, Langer C, Muller S, Schoepfer J, Garcia-Echeverria C, Quadt C, Jensen MR, Einsele H and Bargou RC. Anti-myeloma activity of the novel 2-aminothienopyrimidine Hsp90 inhibitor NVP-BEP800. Br J Haematol. 2009; 147(3):319- 327.
173. Davenport EL, Zeisig A, Aronson LI, Moore HE, Hockley S, Gonzalez D, Smith EM, Powers MV, Sharp SY, Workman P, Morgan GJ and Davies FE. Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma. Leukemia. 2010; 24(10):1804-1807.
174. Yasui H, Hideshima T, Ikeda H, Jin J, Ocio EM, Kiziltepe T, Okawa Y, Vallet S, Podar K, Ishitsuka K, Richardson PG, Pargellis C, Moss N, Raje N and Anderson KC. BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth. Br J Haematol. 2007; 136(3):414- 423.
175. Chauhan D, Li G, Hideshima T, Podar K, Mitsiades C, Mitsiades N, Catley L, Tai YT, Hayashi T, Shringarpure R, Burger R, Munshi N, Ohtake Y, Saxena S and Anderson KC. Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood. 2003; 102(9):3379-3386.
176. Chauhan D, Li G, Shringarpure R, Podar K, Ohtake Y, Hideshima T and Anderson KC. Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS- 341 resistance in lymphoma cells. Cancer Res. 2003; 63(19):6174-6177.
177. Hideshima T, Podar K, Chauhan D, Ishitsuka K, Mitsiades C, Tai YT, Hamasaki M, Raje N, Hideshima H, Schreiner G, Nguyen AN, Navas T, Munshi NC, Richardson PG, Higgins LS and Anderson KC. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene. 2004; 23(54):8766- 8776.
178. Powers MV, Valenti M, Miranda S, Maloney A, Eccles SA, Thomas G, Clarke PA and Workman P. Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX. Oncotarget. 2013; 4(11):1963-1975.
179. Chatterjee M, Andrulis M, Stuhmer T, Muller E, Hofmann C, Steinbrunn T, Heimberger T, Schraud H, Kressmann S, Einsele H and Bargou RC. The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma. Haematologica. 2012; 98(7):1132-1141.
180. Zhang L, Fok JJ, Mirabella F, Aronson LI, Fryer RA, Workman P, Morgan GJ and Davies FE. Hsp70 inhibition induces myeloma cell death via the intracellular accumulation of immunoglobulin and the generation of proteotoxic stress. Cancer Lett. 2013; 339(1):49-59.
181. Braunstein MJ, Scott SS, Scott CM, Behrman S, Walter P, Wipf P, Coplan JD, Chrico W, Joseph D, Brodsky JL and Batuman O. Antimyeloma Effects of the Heat Shock Protein 70 Molecular Chaperone Inhibitor MAL3-101. J Oncol. 2011; 2011:232037.
182. Powers MV, Clarke PA and Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell. 2008; 14(3):250-262.
183. Dai C, Whitesell L, Rogers AB and Lindquist S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell. 2007; 130(6):1005-1018.
184. Heimberger T, Andrulis M, Riedel S, Stuhmer T, Schraud H, Beilhack A, Bumm T, Bogen B, Einsele H, Bargou RC and Chatterjee M. The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma. Br J Haematol. 2012; 160(4):465-476.
185. Lauria A, Ippolito M and Almerico AM. Inside the Hsp90 inhibitors binding mode through induced fit docking. J Mol Graph Model. 2009; 27(6):712-722.
186. Garcia-Carbonero R, Carnero A and Paz-Ares L. Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol. 2013; 14(9):e358-369.
187. Mimnaugh EG, Xu W, Vos M, Yuan X, Isaacs JS, Bisht KS, Gius D and Neckers L. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther. 2004; 3(5):551-566.
188. Siegel D, Jagannath S, Vesole DH, Borello I, Mazumder A, Mitsiades C, Goddard J, Dunbar J, Normant E, Adams J, Grayzel D, Anderson KC and Richardson P. A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. Leuk Lymphoma. 2011; 52(12):2308-2315.
189. Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, Pak RH, Ali JA, Dembski MS, Hudak J, Patterson J, Penders C, Pink M, Read MA, Sang J, Woodward C, et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci U S A. 2006; 103(46):17408-17413.
190. Ishii T, Seike T, Nakashima T, Juliger S, Maharaj L, Soga S, Akinaga S, Cavenagh J, Joel S and Shiotsu Y. Antitumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J. 2012; 2(4):e68.
191. Lamottke B, Kaiser M, Mieth M, Heider U, Gao Z, Nikolova Z, Jensen MR, Sterz J, von Metzler I and Sezer O. The novel, orally bioavailable HSP90 inhibitor NVPHSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases. Eur J Haematol. 2012; 88(5):406-415.
192. Stuhmer T, Iskandarov K, Gao Z, Bumm T, Grella E, Jensen MR, Einsele H, Chatterjee M and Bargou RC. Preclinical activity of the novel orally bioavailable HSP90 inhibitor NVP-HSP990 against multiple myeloma cells. Anticancer Res. 2012; 32(2):453-462.
193. Reddy N, Voorhees PM, Houk BE, Brega N, Hinson JM, Jr. and Jillela A. Phase I trial of the HSP90 inhibitor PF- 04929113 (SNX5422) in adult patients with recurrent, refractory hematologic malignancies. Clin Lymphoma Myeloma Leuk. 2013; 13(4):385-391.
194. Beebe K, Mollapour M, Scroggins B, Prodromou C, Xu W, Tokita M, Taldone T, Pullen L, Zierer BK, Lee MJ, Trepel J, Buchner J, Bolon D, Chiosis G and Neckers L. Posttranslational modification and conformational state of heat shock protein 90 differentially affect binding of chemically diverse small molecule inhibitors. Oncotarget. 2013; 4(7):1065-1074.
195. Usmani SZ, Bona RD, Chiosis G and Li Z. The antimyeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1. J Hematol Oncol. 2010; 3:40.
196. Fewell SW, Smith CM, Lyon MA, Dumitrescu TP, Wipf P, Day BW and Brodsky JL. Small molecule modulators of endogenous and co-chaperone-stimulated Hsp70 ATPase activity. J Biol Chem. 2004; 279(49):51131-51140.
197. Massey AJ, Williamson DS, Browne H, Murray JB, Dokurno P, Shaw T, Macias AT, Daniels Z, Geoffroy S, Dopson M, Lavan P, Matassova N, Francis GL, Graham CJ, Parsons R, Wang Y, et al. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells. Cancer Chemother Pharmacol. 2009; 66(3):535-545.
198. Chen Y, Chen J, Loo A, Jaeger S, Bagdasarian L, Yu J, Chung F, Korn J, Ruddy D, Guo R, McLaughlin ME, Feng F, Zhu P, Stegmeier F, Pagliarini R, Porter D, et al. Targeting HSF1 sensitizes cancer cells to HSP90 inhibition. Oncotarget. 2013; 4(6):816-829.
199. de Billy E, Powers MV, Smith JR and Workman P. Drugging the heat shock factor 1 pathway: exploitation of the critical cancer cell dependence on the guardian of the proteome. Cell Cycle. 2009; 8(23):3806-3808.
200. de Billy E, Travers J and Workman P. Shock about heat shock in cancer. Oncotarget. 2012; 3(8):741-743.